Cariprazine in Bipolar Disorder and Substance Use: A Dual Approach to Treatment? DOI Creative Commons
Simone Pardossi, Alessandro Cuomo,

Despoina Koukouna

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(11), P. 1464 - 1464

Published: Oct. 31, 2024

Bipolar disorder (BD) is characterized by recurrent episodes of mania, hypomania, and depression often complicated comorbid substance use disorders (SUDs). Up to 60% individuals with BD experience SUDs, which exacerbate mood instability increase the risk rapid cycling, suicide, poor clinical outcomes. Current treatment strategies, including lithium valproate, show limited efficacy in treating both SUD. Psychotherapeutic approaches such as cognitive behavioral therapy (CBT) offer benefits but lack a specific focus on substances cannabis cocaine. Since there still debate how treat this comorbidity, need find new therapeutic options; mini-review examines pharmacological properties cariprazine its emerging role Cariprazine, an atypical antipsychotic partial agonism at dopamine D2 D3 receptors, has shown promise symptoms dysfunction BD. Its unique affinity for are involved motivation reward processing, may advantages reducing drug craving. Clinical trials indicate that effectively treats manic, depressive, mixed favorable side effect profile, particularly lower doses. Preliminary results suggest potential reduce craving co-occurring Therefore, cariprazine, pharmacodynamic mechanism, could be further studied comorbidity However, evidence SUDs remains limited, based primarily case reports animal studies. Further research, large-scale trials, needed determine full dual diagnosis.

Language: Английский

Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazine DOI Creative Commons
Alessandro Cuomo, Giovanni B. Forleo,

Taieb Ghodhbane

et al.

Annals of General Psychiatry, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 12, 2025

Schizophrenia is a highly heterogeneous disease, and high percentage of patients are at risk developing somatic comorbidities, which must be taken into account in disease management treatment selection. Antipsychotics often associated with side effects that worsen the comorbidities. Among different options, cariprazine generally safe usually well tolerated both acute long-term good choice when balancing clinical benefits effects. Given lack consensus on priority symptoms to treat reasons for switching therapy based balance between symptom resolution, twelve psychiatrists met an expert meeting discuss most common worrisome antipsychotic leading switching, important best way address specific maintenance phases schizophrenia. Special attention was given metabolic sexual dysfunction, cardiovascular disease. This paper aims examine relationship schizophrenia how efficacy tolerability influences schizophrenia, these two variables may have priorities stages treatment. The primarily tolerability. Cariprazine beneficial positive negative symptoms, it has side-effect profile low rates effects, sedation, dysfunction.

Language: Английский

Citations

0
Synaptic Imbalance in Schizophrenia, a Major Driver of Disability DOI
Agenor Limón

Published: Dec. 27, 2024

Language: Английский

Citations

0
Cariprazine in Bipolar Disorder and Substance Use: A Dual Approach to Treatment? DOI Creative Commons
Simone Pardossi, Alessandro Cuomo,

Despoina Koukouna

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(11), P. 1464 - 1464

Published: Oct. 31, 2024

Bipolar disorder (BD) is characterized by recurrent episodes of mania, hypomania, and depression often complicated comorbid substance use disorders (SUDs). Up to 60% individuals with BD experience SUDs, which exacerbate mood instability increase the risk rapid cycling, suicide, poor clinical outcomes. Current treatment strategies, including lithium valproate, show limited efficacy in treating both SUD. Psychotherapeutic approaches such as cognitive behavioral therapy (CBT) offer benefits but lack a specific focus on substances cannabis cocaine. Since there still debate how treat this comorbidity, need find new therapeutic options; mini-review examines pharmacological properties cariprazine its emerging role Cariprazine, an atypical antipsychotic partial agonism at dopamine D2 D3 receptors, has shown promise symptoms dysfunction BD. Its unique affinity for are involved motivation reward processing, may advantages reducing drug craving. Clinical trials indicate that effectively treats manic, depressive, mixed favorable side effect profile, particularly lower doses. Preliminary results suggest potential reduce craving co-occurring Therefore, cariprazine, pharmacodynamic mechanism, could be further studied comorbidity However, evidence SUDs remains limited, based primarily case reports animal studies. Further research, large-scale trials, needed determine full dual diagnosis.

Language: Английский

Citations

0